Found 1 Presentation For Request "1284P"
1284P - MET inhibitor capmatinib plus EGFR tyrosine kinase inhibitor nazartinib for EGFR-mutant non-small cell lung cancer
- Enriqueta Felip (Barcelona, Spain)
Abstract
Background
In patients (pts) with
Methods
In Ph 2, stage IIIB/IV NSCLC pts (≥ 18 years; ECOG PS ≤ 1; activating
Results
As of Feb 5, 2019, 52 and 47 pts were enrolled in groups 1 and 3, respectively. Group 1 + Ph 1b RP2D group enrolled 68 pts (66 had known MET status: 23
Post-EGFR TKI Tx-naive Group 1 N = 52 Group 1 + Ph 1b RP2D N = 68 N = 47 Baseline characteristics Caucasian, % 55.8 56.5 46.5 66 Never smokers, % 69.2 69.6 62.8 55.3 ≥ 2 prior tx,% 32.7 43.5 30.2 -- Baseline central nervous system metastasis, % 36.5 26.1 37.2 27.7 Primary Efficacy Endpoint ORR [95% CI], % 28.8 [17.1, 43.1] 43.5 [23.2, 65.5] 27.9 [15.3, 43.7] 61.7 [46.4, 75.5] Secondary Efficacy Endpoints Median DOR [95% CI], months 6.3 [3.7, 10.8] 6.3 [3.6, 10.8] 9.3 [3.7, 40.4] 11.6 [6.6, 14.3] Median PFS [95% CI], months 5.6 [3.7, 7.4] 7.7 [5.4, 12.2] 5.4 [3.5, 6.4] 11.0 [7.6, 13.8] Median OS [95% CI], months 18.8 [14.9, 21.7] 18.8 [14.0, 21.3] 17.2 [12.5, NE] NE [15.9, NE]
Conclusions
Efficacy observed in tx-naive pts (Group 3) does not seem to support addition of a MET inhibitor to EGFR TKI in MET unselected pts vs EGFR TKI alone. In
Clinical trial identification
NCT02335944.
Editorial acknowledgement
Editorial assistance was provided by Aarti Kamaraj (Novartis Healthcare Pvt. Ltd.).
Legal entity responsible for the study
Novartis Pharmaceuticals.
Funding
Novartis Pharmaceuticals.
Disclosure
E. Felip: Advisory/Consultancy: Pfizer, Roche, Boehringer Ingelheim, AstraZeneca, Bristol-Myers Squibb, Guardant Health, Novartis, Takeda, AbbVie, Blueprint Medicines, Lilly, Merck Kgaa, Merck Sharp & Dohme, Janssen, Samsung ; Speaker Bureau/Expert testimony: Pfizer, Roche, AstraZeneca, Bristol-Myers Squibb, Novartis, Takeda, Lilly, Merck Sharp & Dohme, Medscape, Prime Oncology, Touchtime ; Research grant/Funding (self): Fundación Merck Salud, Grant for Oncology Innovation (GOI) ; Officer/Board of Directors, Independent member: Grífols . R. Soo: Honoraria (self): AstraZeneca, BMS, Boehringer Ingelheim, Celgene, Ignyta, Lilly, Merck, Novartis, Pfizer, Roche, Taiho, Takeda, Yuhan), Honararia (Institution) (AbbVie, AstraZeneca, Bayer, BMS, Boehringer Ingelheim, Ignyta, Merck, Merck Serono, Novartis, Pfizer, Roche, Ta; Research grant/Funding (self): AstraZeneca, Boehringer Ingelheim ; Research grant/Funding (institution): AbbVie, AstraZeneca, Bayer, BMS, Boehringer Ingelheim, Ignyta, Merck, Merck Serono, Novartis, Pfizer, Roche, Takeda, Yuhan. J. Wolf: Honoraria (self), Speaker Bureau/Expert testimony, Travel/Accommodation/Expenses: AbbVie, Amgen, AstraZeneca, Blueprint, BMS, Boehringer Ingelheim, Chugai, Ignyta, Janssen, Lilly, Loxo, MSD, Novartis, Pfizer, Roche, Takeda; Research grant/Funding (institution): BMS, Janssen, Novartis, Pfizer, Roche . B. Solomon: Honoraria (self): Novartis, AstraZeneca, Roche-Genentech, Bristol-MyersSquibb, Merck, Loxo Oncology, Gritstone Oncology ; Honoraria (institution): Pfizer, Bristol-Myers Squibb; Advisory/Consultancy: Novartis, AstraZeneca, Roche-Genentech, Bristol-Myers Squibb, Merck, Loxo Oncology, Gritstone Oncology, Pfizer. D.S.W. Tan: Honoraria (self): Merck, Pfizer, Novartis, Boehringer Ingelheim, Roche, Takeda; Advisory/Consultancy: Novartis, Bayer, Boehringer Ingelheim, Celgene, AstraZeneca, Eli-lily, Loxo; Research grant/Funding (self): Novartis, AstraZeneca, GlaxoSmithKline, Bayer, Pfizer; Travel/Accommodation/Expenses: Merck, Pfizer, Novartis, Boehringer Ingelheim, Roche,Takeda. A. Ardizzoni: Honoraria (self): BMS, MSD, Roche, AstraZeneca, Eli Lilly; Research grant/Funding (institution): Celgene, BMS, Ipsen, Roche. D.H. Lee: Non-remunerated activity/ies: Blueprint Medicine, Takeda; Advisory/Consultancy, Personal fees: AstraZeneca, Boehringer Ingelheim, Bristol-Myers Squibb, CJ Healthcare, Eli Lilly, ChongKeunDang, Janssen, Merck, MSD, Mundipharma, Novartis, Ono, Pfizer, Roche, Samyang Biopharm, ST Cube, AbbVie, Takeda, Genexine, Menarini, BC Pharma. L.V. Sequist: Research grant/Funding (self): AZ, Merrimack Pharmaceuticals, Genentech, BI, Loxo, Blueprint medicines, Novartis; Advisory/Consultancy: Janssen, AZ, Merrimack Pharmaceuticals, Genentech. F. Barlesi: Honoraria (self): AstraZeneca, Bayer, Bristol-Myers Squibb, Boehringer–Ingelheim, Eli Lilly Oncology, F. Hoffmann–La Roche Ltd, Novartis, Merck, MSD, Pierre Fabre, Pfizer and Takeda; Honoraria (institution): AbbVie, ACEA, Amgen, AstraZeneca, Bayer, Bristol-Myers Squibb, Boehringer–Ingelheim, Eisai, Eli Lilly Oncology, F. Hoffmann–La Roche Ltd, Genentech, Ipsen, Ignyta, Innate Pharma, Loxo, Novartis, MedImmune, Merck, MSD, Pierre Fabre, Pfizer, Sanofi-Aventis. L. Paz-Ares: Advisory/Consultancy, Speaker Bureau/Expert testimony, Personal fees (Scientific advice/Speaker): Lilly, MSD, Roche, PharmaMar, Merck, AstraZeneca, Novartis, Boehringer Ingelheim, Celgene, Servier, Sysmex, Amgen, Incyte, Pfizer, Ipsen, Adacap, Sanofi, Bayer, Blueprint, Bristol-Myers Squibb; Research grant/Funding (self): MSD, AstraZeneca, Pfizer, Bristol-Myers Squibb; Advisory/Consultancy, Advisory board: Genomica; Officer/Board of Directors, Co-founder and Board member: Altum Sequencing. D. Rodriguez-Abreu: Honoraria (self), Advisory/Consultancy: Roche, AstraZeneca, Bristol-Myers Squibb, MSD, Eli Lilly, Pfizer, and Novartis; Travel/Accommodation/Expenses: Roche, Bristol-Myers Squibb, MSD and Novartis; Research grant/Funding (self): BMS. M.R. Garcia Campelo: Honoraria (self): MSD, Bristol-Myers, Roche, Boehringer Ingelheim, Pfizer, Novartis, AstraZeneca, Lilly, Takeda; Advisory/Consultancy: MSD, Bristol-Myers, Roche, Boehringer Ingelheim, Pfizer, Novartis, AstraZeneca, Lilly, Takeda; Speaker Bureau/Expert testimony: MSD, Bristol-Myers, Roche, Boehringer Ingelheim, Pfizer, Novartis, AstraZeneca, Lilly, Takeda. M. Sprauten: Honoraria (self): AstraZeneca, Pierre Fabre, Pfizer; Honoraria (institution): Roche, Astra, Pierre Fabre, Pfizer; Advisory/Consultancy: AstraZeneca.L. O’Sullivan Djentuh: Full/Part-time employment: Novartis Pharma AG. R. Belli: Shareholder/Stockholder/Stock options, Full/Part-time employment: Novartis. S. Glaser: Full/Part-time employment: Novartis; Shareholder/Stockholder/Stock options: Novartis, Alcon. M. Zou: Full/Part-time employment: Novartis. M. Giovannini: Full/Part-time employment: Novartis. J.C-H. Yang: Honoraria (self): Boehringer Ingelheim, Eli Lilly, Roche/Genentech/Chugai, MSD, Novartis, BMS, Ono pharmaceutical, AstraZeneca, Takeda Oncology; Advisory/Consultancy: Boehringer Ingelheim, Eli Lilly, Bayer, Roche/Genentech/Chugai, MSD, Merck Serono, Pfizer, Novartis, Celgene, Yuhan Pharmaceuticals, BMS, Ono Pharmaceutical, Daiichi Sankyo, AstraZeneca, Takeda Oncology, Blueprint Medicines, Hansoh Pharmaceutical, G1 The. All other authors have declared no conflicts of interest.